Breast Cancer Research and Treatment

, Volume 141, Issue 3, pp 477–484 | Cite as

Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers

  • Jun Sang Lee
  • Seho Park
  • Ji Min Park
  • Jung Hoon Cho
  • Seung Il Kim
  • Byeong-Woo ParkEmail author


To investigate the prognostic value of tumor markers, cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels at diagnosis of systemic recurrence. After primary treatments of locoregional breast cancers, serum CA 15-3 and/or CEA concentrations were regularly measured, and systemic recurrences were identified in 351 patients between January 1999 and December 2009. The association between tumor marker levels at systemic recurrence and survival were investigated by univariate and multivariate analyses. Elevated CA 15-3 and CEA levels were identified in 194 of 349 (55.6 %) and 111 of 308 (36.0 %) patients, respectively, at diagnosis of systemic recurrence. Elevated levels of CA 15-3 and CEA were correlated with visceral or multiple recurrences and elevated preoperative levels. Elevation of CA 15-3 was more prominent in younger patients and in primary node-positive tumors, while CEA was elevated in older patients at diagnosis and in estrogen receptor (ER)-positive tumors. Elevated tumor markers as well as ER negativity, short disease-free interval, and advanced stage at initial diagnosis showed independent prognostic significance on multivariate analysis. Among 306 patients for whom levels of both tumor markers at recurrence were available, 106 patients without elevation of either marker showed significantly better overall survival than those with elevated levels of either one or both markers, and the significance persisted in multivariate analysis. Elevated serum CA 15-3 and CEA levels at recurrence suggest increased tumor burden and may be prognostic for survival for metastatic breast cancer patients.


Breast carcinoma CA 15-3 CEA Prognostic factors Tumor marker Systemic recurrence 


Conflict of interest

The authors have declared no relevant conflicts of interest.


  1. 1.
    Parker C (2004) Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 5:101–106. doi: 10.1016/s1470-2045(04)01384-1 PubMedCrossRefGoogle Scholar
  2. 2.
    Duffy MJ (1999) CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36(Pt 5):579–586PubMedGoogle Scholar
  3. 3.
    Cheung KL, Graves CR, Robertson JF (2000) Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 26:91–102. doi: 10.1053/ctrv.1999.0151 PubMedCrossRefGoogle Scholar
  4. 4.
    Nicolini A, Carpi A (2000) Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol 21:235–248PubMedCrossRefGoogle Scholar
  5. 5.
    Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345–351. doi: 10.1373/clinchem.2005.059832 PubMedCrossRefGoogle Scholar
  6. 6.
    Park BW, Oh JW, Kim JH et al (2008) Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 19:675–681. doi: 10.1093/annonc/mdm538 PubMedCrossRefGoogle Scholar
  7. 7.
    Laessig D, Nagel D, Heinemann V et al (2007) Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 27:1963–1968PubMedGoogle Scholar
  8. 8.
    Soletormos G, Nielsen D, Schioler V et al (2004) Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 40:481–486. doi: 10.1016/j.ejca.2003.10.015 PubMedCrossRefGoogle Scholar
  9. 9.
    Molina R, Zanon G, Filella X et al (1995) Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36:41–48PubMedCrossRefGoogle Scholar
  10. 10.
    Nicolini A, Tartarelli G, Carpi A et al (2006) Intensive post-operative follow-up of breast cancer patients with tumour markers: cEA, TPA or CA 15.3 vs MCA and MCA-CA 15.3 vs CEA-TPA-CA 15.3 panel in the early detection of distant metastases. BMC Cancer 6:269. doi: 10.1186/1471-2407-6-269 PubMedCrossRefGoogle Scholar
  11. 11.
    Bast RC Jr, Ravdin P, Hayes DF et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878PubMedGoogle Scholar
  12. 12.
    Molina R, Auge JM, Escudero JM et al (2010) Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 31:171–180. doi: 10.1007/s13277-010-0025-9 PubMedCrossRefGoogle Scholar
  13. 13.
    Sturgeon CM, Hoffman BR, Chan DW et al (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 54:e1–e10. doi: 10.1373/clinchem.2007.094144 PubMedCrossRefGoogle Scholar
  14. 14.
    Harris L, Fritsche H, Mennel R et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312. doi: 10.1200/jco.2007.14.2364 PubMedCrossRefGoogle Scholar
  15. 15.
    Kataja V, Castiglione M (2009) Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):10–14. doi: 10.1093/annonc/mdp114 PubMedGoogle Scholar
  16. 16.
    Lee JS, Park S, Park JM et al (2012) Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol 24:1225–1231. doi: 10.1093/annonc/mds604 PubMedCrossRefGoogle Scholar
  17. 17.
    McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184. doi: 10.1093/jnci/dji237 PubMedCrossRefGoogle Scholar
  18. 18.
    Hayes DF, Zurawski VR Jr, Kufe DW (1986) Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542–1550PubMedGoogle Scholar
  19. 19.
    Robertson JF, Pearson D, Price MR et al (1990) Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer 26:1127–1132PubMedCrossRefGoogle Scholar
  20. 20.
    Robertson JF, Pearson D, Price MR et al (1991) Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 33:403–410PubMedCrossRefGoogle Scholar
  21. 21.
    Williams MR, Turkes A, Pearson D et al (1988) The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. Eur J Surg Oncol 14:417–422PubMedGoogle Scholar
  22. 22.
    Fletcher RH (1986) Carcinoembryonic antigen. Ann Intern Med 104:66–73PubMedCrossRefGoogle Scholar
  23. 23.
    Sturgeon CM, Lai LC, Duffy MJ (2009) Serum tumour markers: how to order and interpret them. BMJ 339:b3527. doi: 10.1136/bmj.b3527 PubMedCrossRefGoogle Scholar
  24. 24.
    Fehm T, Jager W, Kramer S et al (2004) Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res 24:1987–1992PubMedGoogle Scholar
  25. 25.
    Ali SM, Leitzel K, Chinchilli VM et al (2002) Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 48:1314–1320PubMedGoogle Scholar
  26. 26.
    Yerushalmi R, Tyldesley S, Kennecke H et al (2012) Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol 23:338–345. doi: 10.1093/annonc/mdr154 PubMedCrossRefGoogle Scholar
  27. 27.
    Tampellini M, Berruti A, Gerbino A et al (1997) Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 75:698–702PubMedCrossRefGoogle Scholar
  28. 28.
    Gion M, Boracchi P, Dittadi R et al (2002) Prognostic role of serum CA 15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38:1181–1188. doi: S0959804901004269 PubMedCrossRefGoogle Scholar
  29. 29.
    Kim HS, Park YH, Park MJ et al (2009) Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat 118:89–97. doi: 10.1007/s10549-009-0377-2 PubMedCrossRefGoogle Scholar
  30. 30.
    Insa A, Lluch A, Prosper F et al (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56:67–78PubMedCrossRefGoogle Scholar
  31. 31.
    Largillier R, Ferrero JM, Doyen J et al (2008) Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 19:2012–2019. doi: 10.1093/annonc/mdn424 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Jun Sang Lee
    • 1
  • Seho Park
    • 1
  • Ji Min Park
    • 1
  • Jung Hoon Cho
    • 1
  • Seung Il Kim
    • 1
  • Byeong-Woo Park
    • 1
    • 2
    Email author
  1. 1.Department of SurgeryYonsei University College of MedicineSeoulRepublic of Korea
  2. 2.Brain Korea 21 Project for Medical ScienceYonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations